⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2298651 | 0.72 | — | — | |
| SCHEMBL2001087 | 0.67 | — | — | |
| SCHEMBL28151351 | 0.67 | — | — | |
| SCHEMBL1815177 | 0.58 | — | — | |
| SCHEMBL127479 | 0.57 | EGFR (0.50) | — | |
| SCHEMBL1837655 | 0.56 | — | — | |
| SCHEMBL561465 | 0.55 | — | — | |
| SCHEMBL23914157 | 0.55 | — | — | |
| SCHEMBL28003243 | 0.55 | EGFR (0.48) | — | |
| SCHEMBL3292267 | 0.55 | PIK3CG (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107490-A1 | HETEROCYCLE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | claimed |
| US-6627626-B2 | Antiinflammation agents and antiarthritic agents colon cancer, and Alzheimer's disease in mammals, preferably humans, dogs, cats and livestock animals. | PFIZER INC. | 2003-09-30 | — | — | US | claimed |
| US-20030144279-A1 | 5-Heterocyclo-pyrazoles | MINICH MARTHA L (US) | 2003-07-31 | — | — | US | claimed |
| WO-2003037352-A1 | 1-PHENYL-5-N-HETEROCYCLYL-PYRAZOLES AS CYCLOOXYGENASE INHIBITORS FOR THE TREATMENT OF INFLAMMATION ASSOCIATED DISORDERS | PFIZER PRODUCTS INC. (US) | 2003-05-08 | — | — | WO | claimed |
| EP-1308161-A1 | 5-N-heterocyclyl-1-(4-sulfonyl-phenyl)-1H-pyrazole derivatives with cyclooxygenase 2 (COX-2) inhibiting activity for the treatment of inflammatory diseases | Pfizer Products Inc. (US) | 2003-05-07 | — | — | EP | claimed |
| WO-2023107490-A1 | HETEROCYCLE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| CN-115260211-A | Thiophene fused ring containing derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-115232144-A | Nitrogen-containing fused ring derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115215867-A | FXIa inhibitor, pharmaceutical composition, preparation method and application thereof | 上海美悦生物科技发展有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-23 | — | — | US | disclosed |
| EP-1308161-B1 | 5-N-heterocyclyl-1-(4-sulfonyl-phenyl)-1H-pyrazole derivatives with cyclooxygenase 2 (COX-2) inhibiting activity for the treatment of inflammatory diseases | PFIZER PROD INC (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-08 | — | — | US | disclosed |
| EP-1466625-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
| US-6627626-B2 | Antiinflammation agents and antiarthritic agents colon cancer, and Alzheimer's disease in mammals, preferably humans, dogs, cats and livestock animals. | PFIZER INC. | 2003-09-30 | — | — | US | disclosed |
| US-20030144279-A1 | 5-Heterocyclo-pyrazoles | MINICH MARTHA L (US) | 2003-07-31 | — | — | US | disclosed |
| WO-2003037352-A1 | 1-PHENYL-5-N-HETEROCYCLYL-PYRAZOLES AS CYCLOOXYGENASE INHIBITORS FOR THE TREATMENT OF INFLAMMATION ASSOCIATED DISORDERS | PFIZER PRODUCTS INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-1308161-A1 | 5-N-heterocyclyl-1-(4-sulfonyl-phenyl)-1H-pyrazole derivatives with cyclooxygenase 2 (COX-2) inhibiting activity for the treatment of inflammatory diseases | Pfizer Products Inc. (US) | 2003-05-07 | — | — | EP | disclosed |